Xi'an Quanao Biotech Co., Ltd.
Free supplier Enterprise Certification
- Free
supplier - 4th
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86-29-86719484
Tel: +86 15529365669
Tel: +86-29-86719484
Tel: +8615529365669
Mobile: +86 17782579994
Tel: +86-29-86719484
Fax: +86-29-86719484
Province/state: Shaanxi
City: Xi'an
Street: B-1604,Juncheng Guoji, Taiyuan Road, Weiyang distirct
MaxCard:
Ms.Nora Yu Ms.YukiCAS NO.965-52-6
98%(25-300)Kilogram98%(301-500)Kilogram98%(501-900)Kilogram
Best price Nifuroxazide Nifuroxazide powder Reliable quality 965-52-6 in China
Nifuroxazide is a nitrofuran antibiotic. It is active against strains of the enteropathogenic bacteria C. jejuni, Salmonella, Y. enterocolitica, Shigella, and E. coli. It inhibits quorum sensing and virulence factor production in P. aeruginosa. Nifuroxazide inhibits STAT3 activity in a reporter assay (IC50 = ~3 µM) and decreases viability of U266 and INA-6 myeloma cells, which have constitutive STAT3 phosphorylation, with EC50 values of approximately 4.5 µM for both. It also decreases viability, migration, and invasion of, and induces apoptosis in, MCF-7, 4T1, and MDA-MB-231 breast cancer cells. Nifuroxazide (50 mg/kg per day) reduces tumor growth and prevents pulmonary metastasis in a 4T1 murine mammary carcinoma model. It also reduces diarrhea, weight loss, and colon inflammation in a rat model of acetic acid-induced ulcerative colitis.
Nifuroxazide is a broad-spectrum antibacterial agent that has been used for the treatment of infectious diarrhea since 1960’s. In 2008, it was discovered that nifuroxazide is a potent inhibitor of the transcription factor STAT3. Since then, the potential of nifuroxazide as an anticancer agent has been investigated.
Nifuroxazide is a nitrofuran compound inhibitor of STAT transcription factor signaling. Nifuroxazide is described to block constitutive phosphorylation of STAT3 by reducing Jak kinase autophosphorylation, decreasing the viability of myeloma cells depending on constitutive STAT3 activity for survival while not affecting normal peripheral blood mononuclear cells. Nifuroxazide produces decreases in tyrosine phosphorylation of Jak2 and Tyk2, and showed no effects on EGF receptor tyrosine kinase or Src kinase, indicating a relative specificity of Nifuroxazide for Jak2 and Tyk2. Nifuroxazide shows no inhibition of Akt or MAPK phosphorylation.
| Item | Specifications |
| Appearance | Bright yellow crystalline powder |
| Solubility | Practically insoluble in water, slightly soluble in alcohol and practically insoluble in methylene chloride |
| Loss on drying | 0.5% Max |
| Heavy metals(Pb) | 0.002% Max |
| Sulphated ash | 0.1% Max |
| Identification by IR | The IR Spectrum confirms with the reference spectrum |
| Related substance | Impurity A ≤0.005%Impurity B ≤0.3%Impurity C ≤0.3%Impurity D ≤0.3%Impurity E ≤0.3%Signal unspecified impurities ≤0.1%Total impurities other than E ≤0.5%Total ≤0.5%Disregard limit ≤0.05% |
| UV.Absorption | The specific absorption at about 367nm is between 940-1000 |
| Residual solvents | Methanol ≤0.3%Alcohol ≤0.5% Acetic acid ≤0.5%NM ≤0.05% |
| Assay (On dried) | 98.5~101.5% |